AZD4721 (RIST4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). AZD4721 has the potential for the research of inflammatory disease[1].
Assessment of Pharmacokinetics (PK) profile of AZD4721 (RIST4721) in rat and dog[1]. In Vivo PK Rat Dog Predicted hepatic metabolic CL (ml/min per kilogram)1.70.80 Observed CL (ml/min per kilogram)2.40.50 CLrenal (mL/min per kilogram)biliary (mL/min per kilogram)intc1.40.6 VSS (l/kg)0.190.15 T1/2 (h) (PO)1.33.7 (2.7)(8.4) F (%)4582
[1]. Gardiner P, et al. Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metab Dispos. 2019;47(8):865-873.